|Biotech Due Diligence||
I am pleased to present another edition of the Biotech Journal Watch [click for archive], as brought to you by some great members of the Twitter community. Enjoy the latest round-up of key scientific and medical publications relevant to the biotech and pharma enthusiast or investor.
Old-Fashioned Advice On The Last Day Of Entrepreneurship Class
David Sable (Forbes)
That Drug Coupon Isn’t Really Clipping Costs
Cynthia Koons and Robert Langreth
Where Is the Cure for the Migraine?
Michele Willens (New York Times)
Unlocking my genome: Was it worth it?
Meg Tirrell (CNBC)
Taxpayers helped fund this $129,000 cancer drug. Should the government help cut the price?
Carolyn Johnson (Washington Post)
The real-time Biotech Valuation Tracker is consistently one of the most popular features here at BiotechDueDiligence. In response to suggestions from readers, I have added some addition information to the table. First, you will find the 52-week low and high prices for each stock. In addition, I have generated a "SENTIMENT" score for each stock on the list. This column simply provided a percentile score between 0-100%, based on where the current stock price is in comparison to the 52-week low (0%) or 52-week high (100%).
Needless to say, there are a good many single-digit sentiment scores at the moment. In case you are wondering, the highest scores on the list - and still well off their highs - are Galapagos $GLPG and Ligand $LGND (had to edit this post to delete $SRPT from this list).
Just in time for the lead-up to the annual JP Morgan Healthcare Conference (follow at #JPM16), the Biotech Tweets of the Week returns to recap the the highlights of the first big news week of 2016. As always, the collection is curated by @23aloha and @BioDueDiligence.
Biotech Tweets of the Week (January 4-, 2016), featuring:
This Time May Be Different: Today’s Biotech Market In Context
Bruce Booth (LifeSciVC)
How do you find a new compound to patent?
Derek Lowe (In the Pipeline)
Can Elizabeth Holmes Save her Unicorn?
Sheelah Kolhatkar and Caroline Chen (Bloomberg Business)
How Theranos Misled Me
Roger Parloff (Fortune)
Why CRISPR-Cas9 is being hailed as the scientific "Breakthrough of the Year"
Deborah Netburn (Los Angeles TImes) $EDIT
F.D.A. Regulator, Widowed by Cancer, Helps Speed Drug Approval
Gardiner Harris (New York Times)